medigraphic.com

2021, Number 3

<< Back Next >>

Rev Mex Anest 2021; 44 (3)

Dronabinol in appetite management and weight loss in patients with terminal cancer, HIV, palliative care and old age. Literature review

Vilchis-Valentín D, Morales-Rabanales AM, Molina-Romero MA, Medina-Castro JM, Cuellar-Garduño N, Camacho-Ramos CE

Language: Spanish
References: 51
Page: 207-214
PDF size: 265.11 Kb.


ABSTRACT

Introduction: Cachexia is a syndrome associated with advanced cancer, HIV, patients on chemotherapy and those who are followed in palliative care. The prevalence is 25% of patients diagnosed with cancer, 26% in those receiving chemotherapy and 14 to 38% of patients with HIV. A mainstay for management is cannabis, due to the effect of delta-9-tetrahydrocannabinol (THC) from which dronabinol, a drug developed to stimulate appetite and weight gain, was derived. The aim of this literature review is to obtain information on cannabinoids and the strongest existing evidence regarding the use of dronabinol in patients who have presented weight and appetite loss. Material and methods: Literature review with PubMed search engine with the keywords Palliative care, Cannabinoids, cachexia, Dronabinol, Appetite, from 1990 to 2018, limited to humans, obtaining 259 articles, eliminating 222 for repetition or low relevance, leaving 37 articles for analysis. Results: out of 37 articles reviewed 9 were experimental studies, 10 systematized reviews, 1 meta-analysis and 16 articles of recommendations and management suggestions. Conclusion: The management of appetite and weight loss in palliative care, HIV, elderly or chemotherapy patients should be multidisciplinary, involving nutritionists, psychologists and physicians, adjusting the management to the individual characteristics manifested. Dronabinol is a drug of first choice for the management of these symptoms when the natural history of the disease is accompanied by nausea, vomiting or pain.


REFERENCES

  1. Aggarwal SK. Use of cannabinoids in palliative medicine. Curr Oncol. 2016;23:S33-S36.

  2. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004;2:305-314; discussion 314-6.

  3. Vigano A, Watanabe S, Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surv. 1994;21:99-115.

  4. Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? Br J Nutr. 2003;90:729-734.

  5. Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88:625-636.

  6. Bruera E. Current pharmacological management of anorexia in cancer patients. Oncology (Williston Park). 1992;6:125-130; discussion 132, 137.

  7. Bruera E. Is the pharmacological treatment of cancer cachexia possible? Support Care Cancer. 1993;1:298-304.

  8. Beal JA. Appetite effect of dronabinol. Journal of Clinical Oncology 1994;12:1524-5.

  9. Gullett N, Rossi P, Kucuk O, et al. Cancer-induced cachexia: a guide for the oncologist. J Soc Integr Oncol. 2009;7:155-169.

  10. Badowski ME, Kwesi YP. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 2018;14:643-651.

  11. Gorter R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology (Williston Park). 1991;5:13-17.

  12. Cardona D. Pharmacological therapy of cancer anorexia-cachexia. Nutr Hosp. 2006;21:17-26.

  13. Mücke M, Weier M, Carter C, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9:220-234.

  14. Wilner LS, Arnold RM. Cannabinoids in the treatment of symptoms in cancer and AIDS #93. J Palliat Med. 2006;9:802-804.

  15. Nauck F, Klaschik E. Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia. Schmerz. 2004;18:S26-30.

  16. Karen Rocco, Food and Drug Administration. Department of Health & Human Services. Anda 78-292.

  17. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11:137-143.

  18. Brand EJ, Zhao Z. Cannabis in Chinese medicine: are some traditional indications referenced in ancient literature related to cannabinoids? Front Pharmacol. 2017;8:108.

  19. Gould J. The cannabis crop. Nature. 2015;525:S2-3.

  20. Beutler JA, Marderosian AH. Chemotaxonomy of cannabis. I. Crossbreeding between cannabis sativa and C. ruderalis, with analysis of cannabinoid content. Econ Bot. 1978;32:387-394.

  21. Fride E, Bregman T, Kirkham TC. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood). 2005;230:225-234.

  22. Huerta LJ, Ortega MJ, Vargas CE, et al. Cannabinoides: desde la ciencia a la controversia. Alerg Asma e Inmunol Pediatr. 2017;26:16-20.

  23. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4:507-530.

  24. Leal-Galicia P, Betancourt D, González-González A, et al. Breve historia sobre la marihuana en Occidente. Rev Neurol. 2018;67:133-140.

  25. Moreau JJ. Du Hachisch et de l'Aliénation Mentale: Études Psychologiques. Fortin, Masson et C., Paris (Francia), 1845. Prefacio de H. E. y sin paginación.

  26. Schluttenhofer C, Yuan L. Challenges towards revitalizing hemp: a multifaceted crop. Trends Plant Sci. 2017;22:917-929.

  27. Kánter CI. Los caminos de la legalización de la marihuana en México.

  28. Sacks N. Case report: the effect of tetrahydrocannabinol on food intake during chemotherapy. J Am Coll Nutr. 1990;9:630-2.

  29. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol onnutritional status inhivinfection. Ann Pharmacother. 1993;27:827-831.

  30. Mattes RD, Engelman K, Shaw LM, et al. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 1994;49:187-195.

  31. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97.

  32. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol. 2002;20:567-573.

  33. Nauck F, Klaschik E. Cannabinoide in der palliativtherapie des anorexie-kachexie-syndroms. Der Schmerz. 2004;18:197-202.

  34. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the cannabis-incachexia-study-group. J Clin Oncol. 2006;24:3394-3400.

  35. DeJesus E, Rodwick BM, Bowers D, et al. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Physicians Aids Care 2007;6:95-100.

  36. Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?--a pilot study. J Nutr Health Aging. 2007;11:195-198.

  37. Riggs PK, Vaida F, Rossi SS, et al. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 2012;1431:46-52.

  38. Bruera E. Clinical management of anorexia and cachexia in patients whit advanced cancer. Oncology. 1992;49:35-42.

  39. Berry EM, Mechoulamb R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. 2002;95:185-190.

  40. Bagshaw SM, Hagen NA. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. J Palliat Care. 2002;18:111-122.

  41. Bruera E, Castro M. Cannabinoids in supportive care: are they necessary? Support Care Cancer. 2003;11:133-134.

  42. Corey S. Recent developments in the therapeutic potential of cannabinoids. P R Health Sci J. 2005;24:19-26.

  43. Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. J Am Med Dir Assoc. 2007;8:363-377.

  44. Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18:1-9.

  45. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;4:CD005175.

  46. Reuter SE, Martin JH. Pharmacokinetics of Cannabis in cancer cachexia-anorexia syndrome. Clin Pharmacokinet. 2016;55:807-812.

  47. Cabeza C, Corsi O, Pérez CP. Are cannabinoids an alternative for cachexia-anorexia syndrome in patients with advanced cancer? Medwave. 2017;17:e7130.

  48. Inui A. Recent development in research and management of cancer anorexia-cachexia syndrome. Gan To Kagaku Ryoho. 2005;32:743-749.

  49. Ernst G, Kongsgaard UE. Use of cannabinoids in palliative medicine. Tidsskr Nor Laegeforen. 2008;128:822-825.

  50. Ahmed AI, Van den Elsen GA, Van der Marck MA, et al. Medicinal use of cannabis and cannabinoids in older adults: where is the evidence? J Am Geriatr Soc. 2014;62:410-411.

  51. Beal JA. Appetite effect of dronabinol. J Clin Oncol. 1994;12:1524-1525.




2020     |     www.medigraphic.com